Polyclonal Antibodies Market Size, Share & Trends Analysis Report by Product (Primary, Secondary), By Application, By Source, By End-user, By Region, And Segment Forecasts, 2023 To 2030

Polyclonal antibodies are complicated mixtures of various antibodies that are typically made by various B-cell clones of an animal. These antibodies are able to recognize and bind to numerous epitopes on a single antigen, which allows them to create lattices with the antigens and trigger precipitation reactions. Polyclonal antibodies are simpler to manufacture and less costly to produce than monoclonal antibodies. Polyclonal antibodies (pAbs) have a wide variety of uses, including biological analyses both qualitative and quantitative as well as diagnostic testing.

Furthermore, polyclonal antibody treatment is used for a wide range of diseases, including cancers like leukaemia, lymphoma, solid tumours, etc., which have created huge opportunities in the market. Additionally, the rising prevalence of infectious diseases, cancer, and growing research on antibodies is expected to drive the global polyclonal antibody market. For instance, according to the American Cancer Society, the U.S. will experience 1.9 million cancer cases and 609,360 cancer-related deaths in 2022. This number indicates, huge demand for development of polyclonal antibodies therapy for treatment of cancer.

The polyclonal antibody industry was significantly impacted by COVID-19. Several countries' trade bans, supply chain disruptions, and government-imposed lockdowns greatly decreased antibody production in the early stages of the pandemic. However, the industry's demand for polyclonal antibodies grew as more crucial players developed the therapy as a protective measure against COVID-19. For instance, in March 2020, GigaGen Inc., a biotech company developing innovative antibody drugs for several diseases, developed a recombinant polyclonal antibody to treat the symptoms of COVID-19. As a result, over the past few years, there has been an increase in demand for polyclonal antibodies. Similarly, Bharat Serums and Vaccines (BSVL) began work on the development of a patented polyclonal antibody formulation for the treatment of Covid-19 in October 2021.

The development of novel therapies against chronic disease has also been the focus of multiple strategic activities by polyclonal antibody manufacturers over the past few months. For instance, in October 2022, Absolute Biotech launched the solid company, by combining leading antibody-focused brands from around the globe together under the name of Absolute Biotech. In order to advance the development and accessibility of highly specific life science reagents, the combined business will take advantage of each brand's distinct antibody expertise. The Absolute Biotech brand family consists of the following companies: Absolute Antibody, LSBio, Nordic-MUbio, Everest Biotech, and Exalpha.

The market is segmented based on product, application, source, end-user, and region. The product segment is divided into primary and secondary. The application segment is bifurcated into research, therapy, and diagnostics. The source segment is divided into rabbits, goats, sheep, and others the end-user segment is divided into pharmaceutical & biotechnology companies, hospitals, diagnostic centers, and academic & research centers.

The market for polyclonal antibodies is expected to grow considerably over the next few years, driven by rising demand from emerging markets such as the U.S., China, and many others. Major marketplaces included North America and Europe, but it's expected that Asia Pacific will end up being the most lucrative region overall.

There are various large as well as many small companies are there in the global polyclonal antibodies market. The majority of the players are focusing on product development and launch as the major strategy to compete with other companies. For instance, in February 2023, Roche launched the ATRX Rabbit Polyclonal Antibody and IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody to determine the mutation status in individuals with brain cancer. Prominent companies operating in the market include Thermo Fisher Scientific Inc., Merck KGaA, Abcam plc, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Cell Signaling Technology Inc., Becton, Dickinson and Company, PerkinElmer Inc., GenScript, BioLegend, Inc., Creative Diagnostics.